Geron Corp
GERN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000886744
No open-market purchases or sales by Geron Corp insiders were filed in the last 90 days; 260 institutions reported holding it in 13F filings for Q2 2026, worth $626.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Geron Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Geron Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Spiegel Robert J. | Director | 205,810 | Jul 1, 2026 | 5 |
| Molineaux Susan | Director | 130,527Indirect | May 26, 2026 | 1 |
| Bir Dawn Carter | Director | – | May 26, 2026 | 1 |
| O'Farrell Elizabeth G. | Director | 26,220Indirect | May 26, 2026 | 1 |
| McDonald John F | Director | – | May 26, 2026 | 1 |
| Williams Timothy | EVP and Chief Legal Officer | – | Apr 14, 2026 | 1 |
| Andrews Patricia S | Director | – | Mar 26, 2026 | 1 |
| Chinoporos Constantine | Director | – | Mar 26, 2026 | 1 |
| Robertson Michelle | EVP, CHIEF FINANCIAL OFFICER | 17,645 | Feb 19, 2026 | 1 |
| Eid Joseph | EVP, R&D; Chief Medical Office | – | Feb 19, 2026 | 1 |
| ElNawawi Ahmed | EVP, Chief Commercial Officer | – | Oct 20, 2025 | 1 |
| Semerjian Harout | President and CEO | – | Aug 8, 2025 | 0 |
| Lawlis V Bryan | Director | 13,300 | May 22, 2025 | 0 |
| Aggarwal Gaurav | Director | 1,970 | May 22, 2025 | 0 |
| Scarlett John A | Chairman, President and CEO | 12,500 | Mar 3, 2025 | 0 |
| Samuels Scott Alan | EVP, Chief Legal Officer | 26,682 | Mar 3, 2025 | 0 |
| Ziegler James | EVP, Chief Commercial Officer | 100,000 | Mar 3, 2025 | 0 |
| Grethlein Andrew J | EVP, Chief Operating Officer | 0 | Feb 20, 2025 | 0 |
| Kapur Anil | EVP, Corp Strategy & CCO | 0 | Jun 12, 2024 | 0 |
| Feller Faye | EVP, Chief Medical Officer | 0 | Jun 12, 2024 | 0 |
| Bloom Olivia Kyusuk | EVP, Chief Financial Officer | 74,588 | Sep 21, 2023 | 0 |
| Eastham Karin | Director | 109,047 | Jan 17, 2023 | 0 |
| Rosenfield Stephen | EVP, Chief Legal Off & Sec | – | Feb 18, 2022 | 0 |
| Rizo Aleksandra | EVP, Chief Medical Officer | – | Feb 18, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Robertson MichelleEVP, CHIEF FINANCIAL OFFICER | SSale | −9.86K | $1.94 | −$19.1K | −35.8%17.6K after | |
| May 13, 2025 (view filing) | May 9 | 4 days | Lawlis V BryanDirector | PPurchase | +13.3K | $1.18 | +$15.7K | New position13.3K after | |
| Mar 3, 2025 (view filing) | Feb 27 | 4 days | Samuels Scott AlanEVP, Chief Legal Officer | PPurchase | +15.0K | $1.61 | +$24.1K | +128.4%26.7K after | |
| Mar 3, 2025 (view filing) | Feb 27 | 4 days | Scarlett John AChairman, President and CEO | PPurchase | +12.5K | $1.77 | +$22.1K | New position12.5K after | |
| Mar 3, 2025 (view filing) | Feb 27 | 4 days | Ziegler JamesEVP, Chief Commercial Officer | PPurchase | +100.0K | $1.60 | +$160.0K | New position100.0K after | |
| Jul 10, 2024 (view filing) | Jul 8 | 2 days | Grethlein Andrew JEVP, Chief Operating Officer | SSale | −674.3K | $4.56 | −$3.08M | −100.0%0 after | |
| Jun 12, 2024 (view filing) | Jun 10 | 2 days | Feller FayeEVP, Chief Medical Officer | SSale | −287.9K | $4.63 | −$1.33M | −100.0%0 after | |
| Jun 12, 2024 (view filing) | Jun 10 | 2 days | Kapur AnilEVP, Corp Strategy & CCO | SSale | −421.9K | $4.65 | −$1.96M | −100.0%0 after | |
| Jun 5, 2024 (view filing) | Jun 4 | 1 day | Scarlett John AChairman, President and CEO | SSale | −600.0K | $4.00 | −$2.40M | −50.0%600.0K after | |
| May 17, 2024 (view filing) | May 15 | 2 days | Lawlis V BryanDirector | SSale | −35.0K | $3.75 | −$131.3K | −100.0%0 after | 10b5-1 |
| Aug 24, 2023 (view filing) | Aug 24 | Same day | O'Farrell Elizabeth G.Director | PPurchase | +6.61K | $2.28 | +$15.1K | +825.9%7.41K after | |
| Aug 24, 2023 (view filing) | Aug 24 | Same day | O'Farrell Elizabeth G.Director | PPurchase | +6.58K | $2.28 | +$15.0K | +33.5%26.2K after | |
| May 11, 2023 (view filing) | May 11 | Same day | Lawlis V BryanDirector | SSale | −35.0K | $3.00 | −$105.0K | −100.0%0 after | 10b5-1 |
| May 1, 2023 (view filing) | May 1 | Same day | Molineaux SusanDirector | SSale | −35.0K | $2.48 | −$86.8K | −100.0%0 after | |
| Feb 10, 2023 (view filing) | Feb 9 | 1 day | Grethlein Andrew JEVP, Chief Operating Officer | SSale | −384.7K | $3.03 | −$1.17M | −100.0%0 after | 2 lots |
| Feb 10, 2023 (view filing) | Feb 8 | 2 days | Bloom Olivia KyusukEVP, Chief Financial Officer | SSale | −400.0K | $3.08 | −$1.23M | −84.3%74.6K after | |
| Feb 10, 2023 (view filing) | Feb 8-10 | 2 days | Scarlett John AChairman, President and CEO | SSale | −1.34M | $3.04 | −$4.07M | −100.0%0 after | 3 lots |